Abstract: Objective To investigate the safety and immunogenicity of COVID-19 vaccination in patients with nonalcoholic fatty liver disease (NAFLD) and patients with primary hepatocellular carcinoma (HCC). Method Ten COVID-19 patients who had been infected with SARS-CoV-2 and people who voluntarily vaccinated with COVID-19 inactivated vaccine (including 30 Healthy people, 30 NAFLD patients and 10 HCC patients) between December 2020 and October 2021 in the Sixth People's Hospital of Shenyang were enrolled in the study. The healthy group and NAFLD group were vaccinated with 3 doses and the HCC group was vaccinated with 2 doses. The neutralizing antibody (nAb) and liver function after each dose were detected, and the T lymphocyte subsets of the healthy group and the HCC group were tested after the first two doses. The occurrence of adverse reactions after vaccination in each group was recorded. The nAb of COVID-19 patients after 6 months' treatment was also detected. Result The nAb level in healthy group, NAFLD group and HCC group increased gradually with the increase of vaccine doses. The nAb level in healthy group and NAFLD group after the third dose of vaccine were higher than those in COVID-19 patients after 6 months' treatment. CD4+T and CD4+T% were increased in both healthy group and HCC group after vaccination, accompanied by an increase of CD8+T. Injection site pain was the most common adverse reaction. Conclusion COVID-19 inactivated vaccination was safety and has good immunogenicity in patients with liver disease. The third dose is especially suitable for a small number of patients with liver diseases who need to increase the vaccine dose to obtain a better response, and specific people who cannot produce immune response by conventional two doses.

Key words: Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Vaccine, Nonalcoholic fatty liver disease, Liver cancer